期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白血病端粒酶活动度与三氧化二砷治疗观察 被引量：1

Observation on activity of telomorase and treatment of arsenic trioxide in leukemia.
下载PDF
导出
摘要 目的观察白血病端粒酶活性与三氧化二砷的治疗效果。方法端粒重复扩增法结合光密度测定和临床治疗观察。结果急性白血病均表现出较高的端粒酶活性,用三氧化二砷治疗后,获得临床血液学缓解及端粒酶活性降低,并在维持缓解间保持较低水平。结论观察端粒酶活动度有助于临床判断病情转归及三氧化二砷的治疗反应。 Objective To evaluate telomerase activity and effect of arsenic trioxide on acute leukemia. Methods The telomeric repeat amplification protocol (TRAP)combined with semiquantitative analysis and clinical obsevation of arsenic trioxide treatment in leukemic patients. Results The strong telomerase activity was observed in leukemia patients. The clinical hematological remission were achieved and telomerase activity was decreased following arsenic trioxide treatment in acute leukemia. Conclusion The telomerase activity is related to clinical effect of arsenic trioxide treatment in leukemia.
作者 王韫芳 郑晓飞 李昕权
机构地区 北京输血医学研究所 北京放射医学研究所 武警总医院血液科
出处 《现代肿瘤医学》 CAS 2005年第3期327-328,共2页 Journal of Modern Oncology
关键词 白血病 端粒酶 三氧化二砷 leukemia telomerase arsenic trioxide
分类号 R733.7 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer[J]. Science, 1994,266:2011～2015.
  • 2Hiyama E, Hiyama K. Clinical utility of telomerase in cancer[J]. Oncogene, 2002,21:643～649.
  • 3Engelhardt M, Mackenzie K, Drullinsky P, et al. Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture[J]. Cancer Res, 2000,60:610～617.
  • 4郑晓飞,李昕权,王升启,孙志贤.正常人白细胞与急性白血病细胞端粒酶分析[J].白血病,1999,8(3):139-141. 被引量：8
  • 5王韫芳,孙红琰,李昕权,王全立.三氧化二砷对NB4及Jurkat细胞系端粒酶活性的抑制效应[J].中国实验血液学杂志,2003,11(4):359-362. 被引量：9
  • 6Li XQ, Ding XZ, Adrian TE.Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression[J]. Pancreas, 2003,27:174～179.

二级参考文献11

  • 1Kyo S, Takakura M, Ishikawa H, et al. Application of telomerase assay for the screening of cervical lesions. Cancer Res, 1997; 57:1863- 1867.
  • 2Nakamura TM, Morin GB, Chapman KB et al. Telomerase catalytic subunit homologs from fission yeast and human. Science, 1997;277 (5328): 955 - 959.
  • 3Viallard JF, Lacombe F, Dupory M, et al. Flow cytometry study of human cyclin B1 and cyclin E expression in leukemic cell lines:cell cycle kinetics and cell localization. Exp Cell Res, 1999; 247:208 - 219.
  • 4Holt SZ, Wright WE, Shay JW, et al. Multiple pathways for the regulation of telomerase activity. Eur J. Cancer, 1997; 33:761 -766.
  • 5Mandal M Kumar R. Bcl-2 modulates telomerase activity. J Bio Chem, 1997 ; 272:14183 - 14187.
  • 6Buchkovich KJ, Greider CW. Telomerase regulation during entry into the cell cycle in normal human T cells. Mol Bio Cell, 1996; 7:1443 - 1454.
  • 7Li H, Zhao LL, Funder JW, et al. Protein phosphatase 2A inhibits nuclear telornerase activity in human breast cancer cells. J Biol Chem, 1997 ; 272:16729 - 16732.
  • 8Kondo S, Tanaka Y, Kondo Y, et al. Antisense telomerase treatment: induction of two distinct pathways, apoptosis and differentiation. FASEB J, 1998; 12:801-811.
  • 9Shen ZX, Chen GQ, Ni JH, et al. Use of arsenic trioxide (As2O3)in the treatment of acute promyelocytic leukemia (APL) : II. Clinical efficacy and pharmacokinetics in the relapsed patients. Blood,1997; 89:3354- 3360.
  • 10Sladowski D, Streer SJ, Clothier RH, et al. An improved MTT assay. J Immunol Methods, 1993; 157:203-207.

共引文献15

同被引文献5

引证文献1

二级引证文献1

现代肿瘤医学
2005年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部